Pfizer (PFE) EBITDA Margin (2009 - 2026)
Pfizer (PFE) posted quarterly EBITDA Margin of 37.39% for Q1 2026, up 82.0% year-over-year from 20.54% in Q1 2025, and down 72.55% quarter-over-quarter from 136.21% in Q4 2025.
Pfizer (PFE) EBITDA Margin (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported EBITDA Margin for 18 consecutive years, with 37.39% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 82.0% year-over-year to 37.39%; the TTM figure through Mar 2026 stood at 1857.53% (up 182902.0% YoY), while the FY2025 annual figure was 346.69%, up 9959.0% from the prior year.
- EBITDA Margin eased to 37.39% in Q1 2026 per PFE's latest filing, from 136.21% in the prior quarter.
- Across five years, EBITDA Margin topped out at 136.21% in Q4 2025 and bottomed at 410.16% in Q4 2023.
- Historically, EBITDA Margin has averaged 53.99% across 5 years, with a median of 36.36% in 2024.
- Annual changes were most pronounced in 2024 — EBITDA Margin soared 23316 bps — and 2025, when it sank 32316 bps.
- Pfizer's EBITDA Margin stood at 47.01% in 2022, then sank by 972 bps to 410.16% in 2023, then jumped by 107 bps to 30.55% in 2024, then surged by 346 bps to 136.21% in 2025, then sank by 73 bps to 37.39% in 2026.
- Business Quant data shows PFE's EBITDA Margin at 37.39% in Q1 2026, 136.21% in Q4 2025, and 39.11% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 5.72% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 124.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 28.37% |
| Mar 29, 2026 | 37.39% |
| Dec 31, 2025 | 136.21% |
| Sep 28, 2025 | 39.11% |
| Jun 29, 2025 | -324.86% |
| Mar 30, 2025 | 36.57% |
| Sep 29, 2024 | 30.55% |
| Jun 30, 2024 | -1.70% |
| Mar 31, 2024 | 36.36% |
| Dec 31, 2023 | -410.16% |
| Jul 2, 2023 | -172.78% |
| Apr 2, 2023 | -196.80% |
| Jul 3, 2022 | 47.01% |
| Apr 3, 2022 | 41.27% |
| Oct 3, 2021 | 35.15% |
| Jul 4, 2021 | 35.67% |
| Apr 4, 2021 | 38.34% |
| Sep 27, 2020 | 33.65% |
| Jun 28, 2020 | 30.04% |
| Mar 29, 2020 | 38.44% |